Logotipo del repositorio
Logotipo del repositorio
 

Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorArias Murillo, Yazmin Rocio
dc.contributor.authorSalinas Nova, Maria Angelica
dc.contributor.authorCaicedo, Tatiana
dc.contributor.authorGalindo-Borda, Marisol
dc.contributor.authorMeneses-Gil, Ximena
dc.contributor.authorMontero, Camilo
dc.contributor.authorGiron, Fernando
dc.contributor.authorPedraza, Nestor
dc.contributor.authorAroca-Martinez, Gustavo
dc.contributor.authorOspina-Martínez, Martha Lucía
dc.contributor.authorMercado-Reyes, Marcela
dc.date.accessioned2024-10-01T16:05:04Z
dc.date.available2024-10-01T16:05:04Z
dc.date.issued2024
dc.description.abstractThe huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with Corona- Vac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment.eng
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1016/j.transproceed.2023.02.034
dc.identifier.issn00411345 (Impreso)
dc.identifier.issn18732623 (Electrónico)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/15724
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0041134523000696?via%3Dihub
dc.language.isoeng
dc.publisherElseviereng
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.sourceTransplantation Proceedingseng
dc.sourceVol. 55 No. 3 Año 2023spa
dc.titleLow performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstagedeng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesPereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20:1800–8.TagedEndeng
dcterms.referencesAkalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med 2020;382:2475–7.TagedEndeng
dcterms.referencesArias-Murillo YR, Benavides-V CA, Salinas-N MA, Osorio- Arango K, Plazas-Sierra C, Cort es JA. SARS-CoV2/COVID-19 infection in transplant recipients and patients on the transplant waiting list in Colombia. Transplant Proc 2021;53:1237–44.TagedEndeng
dcterms.referencesMagicova M, Zahradka I, Fialova M, et al. Determinants of immune response to anti-SARS-CoV-2 mRNA vaccines in kidney transplant recipients: a prospective cohort study. Transplantation 2022;106:842–52.TagedEndeng
dcterms.referencesSanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation 2022;106:821–34.TagedEndeng
dcterms.referencesBenotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti- SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int 2021;99:1487–9.eng
dcterms.referencesBoyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–6.TagedEndeng
dcterms.referencesRozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 2021;27(1173):e1–.e4.TagedEndeng
dcterms.referencesBenotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int 2021;99:1498– 500.TagedEndeng
dcterms.referencesHaskin O, Ashkenazi-Hoffnung L, Ziv N, et al. Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients. Transplantation 2021;105:e226–33.eng
dcterms.referencesCucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant 2021;21:2727–39.TagedEndeng
dcterms.referencesBalcells ME, Le Corre N, Dur an J, et al. Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile. Clin Infect Dis 2022;75:e594–602.TagedEndeng
dcterms.referencesMiele M, Bus a R, Russelli G, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant 2021;21:2919–21.eng
dcterms.referencesMarinaki S, Adamopoulos S, Degiannis D, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:2913–5.TagedEndeng
dcterms.referencesGrupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021;21:2719–26.TagedEndeng
dcterms.referencesHall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:3980–9.TagedEndeng
dcterms.referencesRössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARSCoV- 2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med 2022;386:698–700.eng
dcterms.referencesEren Sadioglu R, Demir E, Evren E, et al. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients. Transpl Infect Dis 2021;23:e13740.eng
dcterms.referencesDheir H, Tocoglu A, Toptan H, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidneytransplant patients. J Med Virol 2022;94: 3176–83.TagedEndeng
dcterms.referencesMariana S, Florencia R, Jose S, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidneytransplant patients. Clin Kidney J 2022;15: 527–33.TagedEndeng
dcterms.referencesBruminhent J, Setthaudom C, Chaumdee P, et al. SARS-CoV- 2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study). Am J Transplant 2022;22:813–22.TagedEndeng
dcterms.referencesSeija M, Rammauro F, Santiago J, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. Clin Kidney J 2022;15: 527–33.TagedEndeng
dcterms.referencesCorreia AL, Leal R, Pimenta AC, et al. The type of SARSCoV- 2 vaccine influences serological response in kidney transplant recipients. Clin Transplant 2022;36:e14585.TagedEndeng
dcterms.referencesPrendecki M, Thomson T, Candice L, et al. Willicombe M in collaboration with the OSC. Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. medRxiv, in press.eng
dcterms.referencesGangappa S, Wrammert J, Wang D, et al. Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transpl Immunol 2019;53:51–60.TagedEndeng
dcterms.referencesOu MT, Boyarsky BJ, Chiang TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking Belatacept. Transplantation 2021;105:2119–23.eng
dcterms.referencesChavarot N, Ouedrani A, Marion O, et al. Poor anti-SARSCoV- 2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with Belatacept. Transplantation 2021;105:e94–5.TagedEndeng
dcterms.referencesAbravanel F, Marion O, Del Bello A, et al. Humoral and cellular immune responses of solid organ transplant patients on Belatacept to three doses of mRNA-based anti-SARS-CoV-2 vaccine. Vaccines (Basel) 2022;10:354.TagedEndeng
dcterms.referencesNoble J, LangelloA, Bouchut W, Lupo J, Lombardo D, Rostaing L. Immune response post−SARS-CoV-2 mRNA vaccination in kidney transplant recipients receiving Belatacept. Transplantation 2021;105:e259–60.eng
dcterms.referencesHammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med 2022;386:1221–9.eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
747.31 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca